Asia/Oceania
Merck Buys Exclusive Rights to Develop Hengrui Pharma's Lp(a) Inhibitor Outside of China
Merck will pay the Chinese pharma company $200 million upfront and up to $1.77 billion in development, regulatory, and commercial milestone payments.
Everest Medicines Cleared by FDA to Study Cancer Vaccine in US Clinical Trials
The mRNA cancer vaccine, EVM14, induces an immune response to multiple tumor-associated antigens.
Angle Hoping to Continue Developing Parsortix HER2 CTC Assay With BlissBio, Eisai
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
In Brief This Week: Count Me In, TeleRare Health, VolitionRx, Ascentage, Atsena, ClearNote Health
News items for the week of March 10, 2025.
Liver Cancer Recurrence Risk Informed by Tumor Microenvironment Spatial Expression Score
The researchers are seeking industry collaborations to accelerate translation of their spatial immune profiling platform into clinical applications.